Clinical Trial Update: Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial comparing Rd (lenalidomide + low-dose dexamethasone) versus VRd (bortezomib + lenalidomide + low-dose dexamethasone) as induction the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: King Faisal Specialist Hospital & Research Center | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED